Health Technology Reassessment: An Overview of Canadian and International Processes
(December 17, 2024)
(December 17, 2024)
Details
Post-Traumatic Stress Disorder (PTSD) occurs as a response to an acute traumatic event or an extreme stressor. Symptoms include fear, helplessness, hyperarousal, re-experiencing of the event, and avoidance of reminders of the event for at least one month. PTSD can be treated with pharmacological and psychological interventions such as cognitive behavioural therapy (CBT). CBT delivered through the Internet (iCBT) may mitigate barriers to accessing face-to-face CBT such as geographical distance or cost of treatment.
Last Updated : January 20, 2020
Reimbursement of Newer Drugs for Type 2 Diabetes in Canada: An Environmental Scan
(December 17, 2024)
Summary
Recently added to the growing spectrum of diabetes mellitus drugs, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists are generally used to supplement treatment with metformin. This Environmental Scan presents the current reimbursement statuses of these medications by publicly funded drug plans in Canada.
Details
This Genome-Wide Sequencing: Ethical Considerations Technology Review was conducted by Canada's Drug Agency in collaboration with Health Quality Ontario (HQO), together with a supporting rapid review of the qualitative evidence of patient preferences.
Last Updated : November 12, 2019
Details
In 2018, around 270,000 Canadians were living with inflammatory bowel disease (IBD), which comprises Crohn’s disease and ulcerative colitis. Several drug classes, including corticosteroids, immunomodulators and anti-inflammatory biologics, can induce and maintain remission of IBD. Canada's Drug Agency has undertaken a series of reviews of the clinical and economic evidence surrounding drugs for IBD to clarify their relative place in therapy and inform appropriate reimbursement criteria by public drug plans.
Last Updated : June 6, 2019
Details
This project aims to retrieve and summarize the formulary status of drugs pertaining to three classes used for the treatment of type 2 diabetes; i.e., dipeptidyl-peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide 1 (GLP-1) agonists. Information will be retrieved from the website of all publicly funded provincial, territorial, and federal drug plans in Canada.
Last Updated : February 27, 2019
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations
(December 17, 2024)
Summary of Recommendation
Recommendations were developed by the Health Technology Expert Review Panel (HTERP) based on evidence reviewed in a Canada's Drug Agency Health technology Assessment (HTA). The HTA included a review of the clinical effectiveness of tisagenlecleucel,1 an economic evaluation for each indication,2,3 an analysis of implementation issues, a review of ethical considerations, and a review of patient perspectives and experiences.4 The HTA was additionally informed by patient group and clinician input submissions.4,5
Details
A 2018 review of pan-Canadian health organizations highlighted the importance of coordinating health technology assessment (HTA) work on non-drug technologies across Canada. The pan-Canadian HTA Collaborative (created in 2011) is a network that includes five Canadian HTA agencies. Collaboration in HTA occurs through this collaborative, as well as through other local networks and relationships. This Environmental Scan will collect information on HTA collaborations in Canada to provide a foundation for further engagement.
The specific objectives are:
Last Updated : September 13, 2019
Details
Axicabtagene ciloleucel is a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and subtypes of DLBCL (e.g., primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymphoma).
Last Updated : August 15, 2019
Details
Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and children and young adults with relapsed or refractory acute lymphoblastic leukemia.
Last Updated : January 15, 2019